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Disturbed microcirculation in the hands of
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Abstract
Background: Utilising fluorescence optical imaging (FOI), the distribution of an intravenously applied colouring
agent indocyanine green (ICG) can be analysed with the potential to identify malperfusion by little to no tissue
enhancement. Systemic sclerosis (SSc) is characterised by the presence of digital ulcers reflecting progressive
vasculopathy.
The objective was to investigate the potential of FOI in the detection of disturbed microcirculation in the hands
and fingers of patients with SSc and to link FOI findings to clinical signs of ischemia such as digital ulcers and
pitting scars.
Methods: In this cross-sectional study, 63 patients with SSc and 26 healthy subjects were examined. FOI was performed
in all 89 individuals and compared to clinical data and capillaroscopic findings assembled for the SSc cohort.
Results: Healthy subjects showed initial ICG signals in their fingertips in 93.6%, SSc patients in 78.5% (limited SSc) and
43.2% (diffuse SSc). Moreover, in SSc patients, FOI findings were significantly associated with a late capillaroscopic
pattern, disseminated SSc features, a diffuse SSc subtype, and the presence of digital ulcers or pitting scars. Intra- and
inter-reader reliability for FOI amounted to κ = 0.786 and κ = 0.834, respectively.
Conclusions: FOI is able to detect areas of reduced microcirculation in patients with SSc with high association to
capillaroscopic findings. The results pave the way for future FOI investigations into its role in the prediction of
complications due to an impaired acral perfusion.
Keywords: Fluorescence optical imaging, Systemic sclerosis, Raynaud’s phenomenon, Disturbed microcirculation,
Digital ulcers, Nailfold capillaroscopy
Significance and innovations
– FOI shows areas of diminished acral perfusion in
patients with systemic sclerosis
– FOI presents a significant association between
diminished perfusion and clinical signs of ischemia
in SSc
– Diminished perfusion in FOI is significantly linked
to capillaroscopic patterns in SSc
– The prevention of digital ulcers in SSc using FOI
should be investigated
Background
Indocyanine green (ICG)-enhanced fluorescence optical
imaging (FOI) is a novel, fast and quantitative imaging
method that is already used in the diagnostics of inflam-
matory arthritis with good agreement to other imaging
modalities (magnetic resonance imaging [MRI], ultra-
sound [US]) and good reliability [1–3]. Light of the
(near)-infrared spectrum enters the tissue of the hands,
where it stimulates the fluorophore ICG. Its fluorescence
* Correspondence: sarah.ohrndorf@charite.de
†Equal contributors
1Department of Rheumatology and Clinical Immunology, Charité University
Hospital, Berlin, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Friedrich et al. Arthritis Research & Therapy  (2017) 19:87 
DOI 10.1186/s13075-017-1300-6
is then detected by a charge-coupled detector (CCD). A
locally increased microcirculation, e.g. in inflamed joints,
leads to strong signal enhancement, due to higher ICG
concentration.
ICG fluorescence video angiography has also been
shown to help in the detection of compromised tissue
perfusion as a perioperative tool in microsurgery [4].
ICG is well tolerated and side effects (i.e. anaphylactic
symptoms) occur rarely (1:42,000) [5]. Shortly after its
administration, ICG is hepatically metabolised and hepa-
tobiliarily excreted. Already since the 1970s, ICG has
safely been used in ophthalmologic angiography and
even proved its value in the evaluation of skin perfusion
in plastic surgery [6].
Pfeil et al. introduced FOI in SSc patients. Compared
to healthy subjects, areas with strong signal enhance-
ment could be observed and were interpreted as tissue
inflammation. A normalisation occurred after prostacyc-
lin treatment [7]. However, these investigations focused
on areas of increased perfusion.
Patients with systemic sclerosis (SSc) typically suffer
from Raynaud’s phenomenon (RP) and progressive oblit-
erative vasculopathy. Both lead to a decreasing or even
completely ceasing circulation in distal body parts, i.e.
fingertips or the nose. Almost one third of SSc patients
consequently develop at least one digital ulcer per year,
[8] which usually causes pain, loss of function, local and
systemic infection and reduced quality of life.
So far, several predictive factors for the development
of digital ulcers (DU) have been described, i.e. diffuse
subtype of SSc, late pattern of capillaroscopy, history of
DU or markers for endothelial dysfunction [9–12]. Vari-
ous imaging methods have been suggested to measure
vasculopathy in patients with systemic sclerosis and to
link its extent to the existence of current or future
digital ulcers. Endothelial function assessed by multisite
photoplethysmography (PPG), cardiovascular assess-
ments and the peripheral blood perfusion assessed by
laser speckle contrast analysis (LASCA) were lower in
SSc patients with digital ulcers than in patients without
[13, 14]. Laser Doppler perfusion imaging is able to de-
tect the therapeutic effects of Bosentan, but could not
differentiate between patients with and without digital
ulcers [15]. The best prospective data exist for nailfold
capillaroscopy (NC): the capillaroscopic skin ulcer risk
index (CSURI) has a high specificity (81.4%) and sensi-
tivity (92.98%) for new or persistent digital ulcers after
3 months (less so in clinical settings without limitations
as to vasoactive treatment), but can only be applied in
patients with megacapillaries [16, 17]. A pilot study of
Smith et al. introduced the assessment of capillaries in
eight specific regions in regard to present and future
digital ulcers [18]. The videoCAPillaroscopy (CAP) mul-
ticentre study found the number of capillaries in the
middle finger of the dominant hand among other capil-
laroscopic covariables to be a predictive factor for the
development of digital ulcers [19]. Other studies focused
on capillaroscopic patterns (i.e. early, active and late)
and found associations to the presence as well as the de-
velopment of digital ulcers [11, 12, 20–24]. While these
studies have not provided concrete values of specifi-
city and sensitivity, we calculated levels of around
36% and 89% respectively using their provided data
[11, 12, 20, 23, 24].
To our knowledge, there has not yet been any investi-
gation into FOI’s potential to detect areas with disturbed
or decreased microcirculation in SSc patients. We there-
fore investigated whether diminished acral perfusion –
as found in patients with systemic sclerosis – was
assessable in FOI, i.e. via areas of reduced enhancement.
This is contradictory to former research using fluores-
cence optical imaging as the main focus so far has been
placed on increased signal intensity typical for inflamma-
tion. FOI findings in SSc patients were compared to
those in healthy individuals and associated with their
SSc subtype, capillaroscopic patterns, 2013 ACR/EULAR
criteria, clinical findings as well as pitting scars (PS) and
DU at baseline as defined by Medsger et al. [25].
Methods
Subjects’ characteristics
Between 2013 and 2015, 89 individuals participated in
this study forming two cohorts: the SSc group and the
healthy cohort. We consecutively included in- and out-
patients fulfilling the 2013 ACR/EULAR criteria for sys-
temic sclerosis. Healthy subjects were defined as persons
without any known diseases, e.g. vascular diseases. For
subjects’ characteristics see Table 1. Subjects with
current DU/PS were summarised in group 1, subjects
without DU/PS in group 2. Exclusion criteria were pro-
gressive renal dysfunction (glomerular filtration rate
[GFR] ≤15 ml/min), latent and manifest hyperthyroidism,
allergies to iodine or contrast agents, pregnancy and being
underage. 2013 ACR/EULAR classification guidelines
were applied with seven different criteria each scoring 2,
3, 4 or 9 points (such as present DU/PS, RP or skin indur-
ation) [26]. A maximum of 30 points could be obtained;
≥9 points confirmed the classification as SSc. We defined
the range of scores between 9 and 30 points as a marker
for dissemination of SSc features: a higher individual
ACR/EULAR score meant the presence of more SSc
characteristics. Limited, limited cutaneous and diffuse
cutaneous SSc (lSSc, lcSSc and dcSSc) were distinguished
according to LeRoy et al. [27].
Organ involvement was evaluated as follows: manifes-
tations of the lung were either pulmonary hypertension
or interstitial lung disease, determined by right heart
catheterisation or echocardiogram and high-resolution
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computed tomography or lung function test, respectively.
Gastrointestinal involvement was defined as dysphagia
and/or radiographic dysmotility and chronic diarrhoea.
Cardiac involvement comprised arrhythmias, congestive
cardiac failure, pericardial effusion, and conduction de-
fects not attributable to other cardiac conditions.
Fluorescence optical imaging
The FOI method Xiralite X4 (mivenion GmbH, Berlin,
Germany) measures the fluorescence of the fluorophore
indocyanine green (ICG, 5% iodine) using light-emitting
diodes and a charge-coupled detector (CCD, a high-
resolution camera). Light with defined wavelengths
(ca. λ = 740 nm) in the (near)-infrared spectrum is
emitted and sent through the observed tissue stimulating
the fluorophore (if present). The fluorophore then emits
fluorescence of different wavelengths (max. λ = 832 nm)
whose photons are detected by CCD. Refracted and
reflected light is filtered out, so that the resulting image
represents a true depiction of ICG distribution in the
tissue [1, 3].
Thus, the method permits a visualisation of different
ICG quantities in the tissue of both hands, e.g. higher
quantities of the agent can be found in inflamed tissue
due to capillary leakage as well as an increase in blood
flow and vessel density on a microvascular level [28].
Low ICG quantity – and therefore low fluorescence
signal – results from poor tissue perfusion.
All participants in this study received FOI examination
following the Xiralite system guidelines (ICG 0.1 mg/kg
Table 1 Characteristics of subjects
Subjects’ characteristics Systemic sclerosis (SSc) Limited (cutaneous) SSc Diffuse cutaneous SSc Healthy cohort
n = 63 n = 40 n = 23 n = 26
Female: n (%) 52 (82.5%) 35 (87.5%) 17 (73.9%) 19 (73.1%)
Mean age in years (±SD) 56.4 (±14.4) 56.4 (±14.9) 56.6 (±13.4) 28.8 (±9.6)
Mean disease duration (in years ± SD) since
First Raynaud’s 13.3 (±12.8) 14.6 (±12.3) 11.1 (±13.6) Not present
First non-Raynaud’s symptoms 9.8 (±9.4) 9.7 (±9.6) 9.8 (±9.3) Not present
Patients with Raynaud’s in the past week
Number of patients (%) 57 (90.4%) 36 (90.0%) 21 (91.3%) Not present
Mean number of episodes (±SD) 15.5 (±22.4) 17.5 (±27.3) 11.9 (±8.8)
Mean impact on day-to-day life using VAS 0-100 (±SD) 36.3 (±29.6) 37.0 (±29.7) 35.1 (±30.1)
Digital ulcers/pitting scars, n (%) 37 (58.7%) 18 (45.0%) 19 (82.6%) Not present
Skin involvement
Mean mRSS ± SD 9.0 (±8.2) 4.6 (±3.5) 16.5 (±8.6) Not present
Organ involvement, n (%)
Lung 23 (36.5%) 9 (22.5%) 14 (60.9%) Not present
Gastrointestinal 42 (66.7%) 25 (62.5%) 17 (73.9%)
Heart 10 (15.9%) 3 (7.5%) 7 (30.4%)
Capillaroscopy pattern, n (%) [21]
Early 11 (17.5%) 9 (22.5%) 2 (8.7%)
Active 25 (39.7%) 18 (45.0%) 7 (30.4%)
Late 24 (38.1%) 11 (27.5%) 13 (56.5%)
Non-SSc 1 (1.6%) 1 (2.5%) 0
Not done 2 (3.2%) 1 (2.5%) 1 (4.3%) 26 (100%)
Current medication, n (%)
Iloprost 38 (60.3%) 27 (67.5%) 11 (47.8%) 0
Oral vasodilating drugsa 42 (66.7%) 25 (62.5%) 17 (73.9%) 0
One patient with limited systemic sclerosis (SSc sine scleroderma) was included in the limited cutaneous SSc subgroup
VAS visual analogue scale, mRSS modified Rodnan skin score
aCalcium channel blockers, AT1 receptor antagonists, ACE inhibitors, endothelin receptor antagonists, PDE-5 inhibitors; alpha receptor antagonists
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BW intravenously, 6 minutes’ duration). Subjects had to
wait in an environment of 20–23 °C for 20 minutes in
order to diminish the risk of an acute Raynaud’s episode.
A peripheral venous catheter, the colouring agent
(0.1 mg/kg BW) as well as a syringe with 10 ml NaCl
0.9% solution were prepared. The subject’s hands were
then placed on a mould underneath the camera with a
curtain lying on the lower arms in order to diminish dis-
turbance by exterior light. The examiner (e.g. a medical
assistant) checked for possible disturbances (e.g. exterior
light, spilled ICG) watching the XiraView® preview,
before starting the examination. FOI began with ten
(reference) images being taken before ICG administra-
tion. Immediately afterwards, 10 ml NaCl 0.9% solution
was applied to introduce the complete amount of ICG
into the blood stream, where ICG binds to 98% onto
plasma proteins. Indocyanine green has a half-life of
3.4 minutes (±0.7) and is hepatically eliminated with a
mean decay of 18.5% per minute (±2.1); 20 minutes after
applications, studies have shown a mere trace (3.8% ± 1.0
of the original dose) to still be found in the body [28].
The infrared camera continued taking one picture per
second for the next 350 seconds, resulting in a total
examination time of 6 minutes. With ICG’s half-life span
and rate of decay one can expect the fluorophore to have
passed through the bloodstream and accumulated in the
observed tissue in this timespan.
FOI analysis
XiraView® was used to conduct the analysis, especially its
360-second-long clip mode, which depicts ICG distribu-
tion in the hands after administration. The PrimaVista-
Mode, a summation image of the examination, was used
for visualisation in this work’s figures.
The number of photons emitted from the fluorophore
is recorded in every pixel. After the examination, these
are proportioned to the reference images (no ICG) and
the pixel with the highest photon emission in the entire
examination. The percentage of the actual emission in
the pixel compared to the maximum emission is used by
the software to create a colour scale for optimal visuali-
sation which we used for our analysis: white and red sig-
nals indicate a strong enhancement (= strong ICG
accumulation in the tissue defined as ≥65% of the indi-
vidual maximum quantity), yellow and green signals in-
dicate a medium enhancement, light blue signals show
lower ICG accumulation in the tissue, dark blue signals
show very little ICG accumulation and no ICG accumu-
lation at all is coded in black. A dark blue or black signal
was considered as an insufficient enhancement due to
low ICG accumulation (<27% of the individual maxi-
mum quantity) in the region (to see the defined regions
please compare Fig. 4) observed. The cutoffs of >65%
and <27% for strong and insufficient signal respectively
were provided by the software as 65% defines the mark
between the red and yellow signal and 27% the mark
between the light and dark blue signal.
Each finger of every subject was separately inspected
(see Figs. 1, 2 and 3)
We evaluated three things in particular:
1. The region of initial enhancement (IE), which was
defined as a finger’s first region presenting a strong
ICG accumulation (≥65% of the individual
maximum quantity; coded as a white or red signal).
Ideally, this region would be the fingertip (region 0,
compare Fig. 4), designating an unperturbed arterial
blood flow. A strong signal below the fingertip
would depict the last area with (supposedly)
unperturbed circulation.
2. The region of maximum distal distribution (MDD),
which was defined as the most distal region that
shows sufficient ICG enhancement (≥27% of the
individual maximum quantity; coded as a white,
red, yellow, green or light blue signal) during the
course of the examination. Ideally, this region would
also be the fingertip (region 0). Signals below would
mean an insufficient provision of blood to more
distal regions due to angiopathy, occlusion etc.
3. Complete disruption: a complete disruption of
acral microcirculation was defined as an insufficient
ICG accumulation (i.e. <27% of maximum signal
intensity) in the fingertip of at least one of the
subject’s finger during the entire examination.
That implies that the region of MDD is more
proximal than the fingertip (i.e. regions 1 to 8,
compare Fig. 4).
We assigned eight regions (region 0 to region 7) to each
finger (thumbs: five regions) starting with the fingertip
(region 0) and ending in the metacarpal region. The wrist
was considered a common region 8 (see Fig. 4).
Furthermore, ICG accumulation patterns for typical
changes during IE as described by Granzow et al. [29]
were scanned. The examination and analysis as de-
scribed were performed in a maximum of 15 minutes
per subject.
Nailfold capillaroscopy
This method was conducted with a USB device (Di-Li
970-O USB hand microscope Di-Li®-Lite; Bresser, Rhede,
Germany) and the MicroCapture V2.0 software (to
determine the capillary density) following current
guidelines. Three distinct capillaroscopic SSc patterns
(early, active, late pattern, compare Fig. 5) as well as
non-SSc-specific findings were identified as defined by
Cutolo et al. [21]. An exact examination via nailfold
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capillaroscopy (NC) usually took our examiners 40
minutes per subject.
Statistical analysis
Statistical analysis was conducted by the statistical soft-
ware SPSS (Version 21.0.0.2; IBM Corp, Armonk, NY,
USA). Mann-Whitney U, Fisher’s exact and X2 tests
were performed. A p value of ≤0.05 was considered
statistically significant.
Intra- and inter-reader reliability
A trained FOI examiner (SF), who assessed the initial
FOI findings directly after the conducted examination,
re-evaluated 20 consecutive patients’ findings in January
2016. A second examiner (SL), who was trained by the
Fig. 1 Fluorescence optical imaging (FOI) staining in a healthy subject. Upper image: initial enhancement (IE), defined as the first strong signal of
indocyanine green (ICG), in digit II of the right hand; IE in the left hand has already taken place. Middle image: area of maximum distal distribution
(MDD) is the fingertip (region 0) in every finger as this is the most distal region with a sufficient ICG signal. Lower image: last image (no. 360) of
the examination; most of the ICG has already disappeared
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first reader, separately evaluated the FOI findings of
these 20 patients. Both examiners were blinded to the
initial results as well as the results of one another. Intra-
and inter-reader reliabilities were calculated using
Cohen’s kappa test.
Results
Healthy subjects present sufficient ICG enhancement in
all digital regions
In the healthy cohort, 242 of 260 fingers (93.1%; Fig. 1)
showed a strong initial enhancement (IE, ≥65% of
maximum signal intensity) in the fingertips (region 0)
with a subsequent expansion of ICG to more proximal
areas (region 1 to region 8; Fig. 4). The other 18 (6.9%)
fingers of the healthy cohort presented a sufficient
ICG accumulation (>27% of maximum signal intensity)
in the fingertips later on, designing a sufficient maxi-
mum distal distribution (MDD) in the entire healthy
cohort.
Pathologic ICG accumulation is related to general
presence of digital ulcers and/or pitting scars in SSc
patients
We observed a strong (≥65% of maximum signal intensity)
initial enhancement (IE) behaviour in both patients with
(n = 37, group 1) and patients without (n = 26, group 2)
current digital ulcers and/or pitting scars (DU/PS) at the
time of the examination. However 67.6% of group 1
(compare lower left image of Fig. 2, e.g. digit III left) and
61.5% of group 2 showed a missing strong signal in region
0 or region 1 (see Fig. 4 for regions) during IE in at least
one finger.
A total of 57.7% of group 1’s fingers showed a strong
initial ICG accumulation in the fingertip (region 0) and
1.9% slightly below the fingertip (region 1, see Fig. 2
upper left image), in contrast to 80.9% and 3.0% of group
2’s fingers respectively (p < 0.0001). Fingers with a strong
IE more proximal than that, were more likely to belong
to patients with current digital ulcers and/or pitting
scars (group 1): between 63.5% and 100% of fingers with
a strong IE in the areas between region 2 (near distal in-
terphalangeal joint, DIP; 74.5%) and region 8 (wrist;
100%) belonged to patients of group 1 (for regions,
compare Fig. 4).
Defining a strong IE in region 2 as a cutoff for patho-
logic enhancement behaviour (strong initial ICG accu-
mulation in proximal areas of the finger/hand instead of
the fingertips as seen in most healthy subjects), we
calculated 40% sensitivity and 84% specificity for the de-
tection of patients with present DU/PS. The positive
predictive value was 73.5%.
Individual finger analysis in SSc patients shows link
between pathologic FOI findings and presence of digital
ulcers and/or pitting scars in the same finger
Individual finger analysis showed a strong IE in the fin-
gertips in 78.5% (n = 314 of 400 fingers) of patients with
lcSSc (compare FOI staining Fig. 3) and in 43.3% (n = 97
of 224 fingers; six not assessable; p < 0.0001) of the pa-
tients with dcSSc (see Fig. 2 for FOI staining; compare
Fig. 2 Fluorescence optical imaging (FOI) staining in a patient with diffuse cutaneous systemic sclerosis. Upper left image: strong initial enhancement (IE)
in digit II of the right hand just below the fingertip (region 1). Lower left image: IE in the digit III of the left hand near the metacarpophalangeal (MCP)
joint (region 6). Upper right image: maximum distal distribution (MDD) in the fingertip (region 0) of digit II of the right hand. Lower right image: MDD in
digit V of both hands with the most distal sufficient signal in region 5 of the left digit V and region 1 of the right hand’s digit V. ICG indocyanine green
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overview of IE regions in Fig. 4b and c). In SSc patients,
a missing initial ICG accumulation in the fingertip sig-
nificantly more often coincided with the presence of at
least one digital ulcer and/or pitting scar in the corre-
sponding finger (see Table 2, exemplary depiction in
Fig. 6): 60.9% of fingers with current DU/PS, 26.1% of
fingers without these complications showed a strong initial
ICG accumulation in more proximal areas (p < 0.0001).
In six fingers of one SSc patient, the initial enhancement
could not be determined due to severe sclerodactyly.
After initial enhancement, the maximum distal distri-
bution (MDD) of ICG was observed. A total of 594 fin-
gers showed a sufficient ICG distribution (i.e. ≥27% of
maximum signal intensity) in the fingertip in the course
of the examination. A complete disruption of ICG accu-
mulation (i.e. <27% of maximum signal intensity in the
fingertip at all times) was found in 26 fingers.
In all fingers with current DU/PS, 11.9% showed a
pathologic MDD (<27% of maximum signal intensity in
the fingertip) compared to only 1.9% in fingers without
DU/PS in the corresponding finger (see Table 2). The
proportion of 1.9% belonged to four patients especially
at risk for the development of future digital ulcers, as
they all shared a history of digital ulcers and at least one
of the following characteristics: DU in other fingers, late
pattern capillaroscopy and diffuse SSc subtype.
Pathologic FOI findings were associated with other
clinical findings
The distribution of ICG differed in patients with SSc
from the healthy cohort. Irregular ICG accumulation
patterns (“islands”) were present in 50.8% (n = 32 of 63)
of SSc patients compared to 21.4% (n = 6 of 28) of the
healthy cohort (p = 0.0112). Furthermore, 66.7% of SSc
Fig. 3 Fluorescence optical imaging (FOI) staining in a patient with lcSSc, without clinically apparent Raynaud’s episode. Upper image: strong
initial enhancement (IE) in digits I, III, IV and V of the right hand; the index finger has not yet accumulated indocyanine green (ICG). Lower image:
maximum distal distribution (MDD) in the fingertip of the right hand’s index finger
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Fig. 4 Regions of initial enhancement in healthy subjects and systemic sclerosis patients. PrimaVistaMode (summation image) of (a) a healthy
subject and exemplary depiction of the nine regions in digit II, left hand with finger-wise percentage of initial enhancement of indocyanine green
(ICG) of the healthy cohort: proper distribution of the colouring agent with 84–100% (mean: 93.1%) of first ICG signals in region 0 (fingertip).
PrimaVistaMode of a patient with (b) limited (cutaneous) systemic sclerosis (lcSSc) and (c) diffuse cutaneous systemic sclerosis (dcSSc) and
depiction of the finger-wise percentage of strong initial ICG enhancement per region (0–8). LcSSc cohort with 69–90% (mean: 78.5%) and
dcSSc cohort with 30–70% (mean: 43.2%) of initial ICG signals in region 0. DIP distal interphalangeal joint, MCP metacarpophalangeal joint,
PIP proximal interphalangeal joint
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(n = 42 of 63 patients) and 25.0% of the healthy cohort
(n = 7 of 28) revealed a missing strong signal in at least
one fingertip during initial enhancement (p = 0.0009).
These 42 SSc patients significantly more often reported
episodes of Raynaud’s phenomenon in the past week
(97.6% vs. 76.2%; p = 0.0134). A complete disruption of
microcirculation of at least one finger (insufficient
MDD) was found in 11 (17.5%) SSc patients, but in none
of the healthy subjects.
As seen in Table 3, the modified Rodnan skin score is
significantly higher in patients with pathologic IE than
in patients with normal IE (p = 0.0234). The same is true
for the MDD (p = 0.0003). Similar results were obtained
when focusing on the hands’ skin scores: at least one
pathologic finger in IE or MDD was significantly associ-
ated with a higher skin score in both hands (IE p =
0.0037; MDD p < 0.0001). Lastly, similar relations could
also be found when analyzing each hand individually: if
one finger had a pathologic IE or MDD, the mean skin
score of the hand (range 0–6) was higher as well.
We also found considerable differences regarding the
total score of ACR/EULAR criteria between SSc patients
presenting a complete disruption and those with suffi-
cient perfusion. Patients with a pathologic MDD pre-
sented a higher mean score (mean: 21.4 points, SD: ±3.6,
95%CI: 18.9–23.8) than those with sufficient ICG accu-
mulation in region 0 (compare Fig. 4) during the course
of the examination (mean: 15.7 points, SD: ±3.9, 95%CI:
14.6–16.8; p = 0.0005).
Capillaroscopy and digital ulcers/pitting scars - increasing
specificity using FOI
Sixty-one of the 63 SSc patients received a nailfold capil-
laroscopy examination. Only one patient showed non-
SSc-specific alterations in their nailfold. An early pattern
was found in 17.5%, an active pattern in 39.7% and a late
pattern in 38.1% of SSc patients (compare Fig. 5). In
total, 77.1% of all assessable fingers showed a decreased
capillary density (<7 capillaries/mm), and 34.1% had one
or more megacapillaries (diameter >50 μm). Thirty-eight
patients presented megacapillaries in at least one finger,
while no megacapillaries could be found in the capillaro-
scopy of 18 patients. Nevertheless, almost half of these
Fig. 5 Typical nailfold capillaroscopy patterns in systemic sclerosis
patients. Exemplary images of the three patterns of nailfold
capillaroscopy as defined by Cutolo et al. [29]: the early pattern
(upper image) is characterised by a normal capillary density and
distribution with few ectasias and haemorrhages. The active pattern
(middle image) is defined by giant capillaries, many haemorrhages and
mild capillary loss and disorganisation. Irregular capillary width, avascular
areas due to decreased capillary density as well as ramified or bushy
capillaries, but less giant capillaries and haemorrhages constitute the
late pattern (lower image)
Table 2 Comparison of fingers with pathologic FOI findings with the presence of current digital ulcers and/or pitting scars (DU/PS)
in the same finger (SSc patients)
Initial enhancement (IE) Maximum distal distribution (MDD)
n
(total)a




Missing or insufficient signal in fingertip
during entire examination, n (%)
Fingers with current DU/PS 138 84 (60.9%) 143 17 (11.9%)
Fingers without current DU/PS 476 124 (26.1%) 477 9 (1.9%)
p value (Fisher’s exact t test) p < 0.0001 p < 0.0001
aNote different n (total) for IE and MDD due to six not assessable values for IE
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18 patients (44.4%) had current DU/PS. A total of 63.2%
of patients with megacapillaries showed DU/PS.
A higher percentage of SSc patients with pathologic
MDD presented a late pattern in the nailfold capillaro-
scopy (81.8% vs. 30.0%, p = 0.0043).
The calculated sensitivity and specificity for nailfold
capillaroscopy were 86.1% and 28.0%, respectively, op-
posing non-SSc and early pattern to active and late pat-
tern in regard to present DU/PS. The positive predictive
value amounted to 63.3%.
Combining the capillaroscopy with an additional FOI
examination revealed the following: while sensitivity
dropped to FOI levels of 40.4%, specificity increased dra-
matically to 88.4%. The positive predictive value im-
proved and rose to 83.1%.
Intra- and inter-reader reliability
The intra-reader reliability amounted to 0.786; only 7.6%
of the initial assessment differed from the second rating
of examiner 1. The inter-reader reliability was 0.834 with
95.7% accordance between the assessments of examiner
1 (second assessment) and examiner 2.
Safety
In the included cohorts, no side effects to ICG applica-
tion were observed.
Discussion
In the present study, fluorescence optical imaging (FOI)
was used to investigate microvasculopathy in SSc. As
presented above, the SSc group was easily distinguish-
able from young healthy subjects by their FOI staining
(compare Figs. 1, 2, 3 and 4). While the healthy cohort
mainly presented a strong initial ICG enhancement in
the fingertips, the SSc group often showed strong initial
ICG signals in more proximal areas. Furthermore, a
complete disruption (i.e. insufficient signal in the finger-
tips in the course of the examination) of digital perfu-
sion was specifically observed in SSc patients. Pathologic
FOI staining was associated with diffuse SSc subtype,
late pattern in NC, a higher modified Rodnan skin score
and a higher total score of ACR/EULAR classification
criteria. Additionally, individual finger analysis revealed
associations with present digital ulcers or pitting scars
(DU/PS) in the corresponding finger. FOI presented a
relatively high specificity regarding its ability to distinguish
Fig. 6 Location of digital ulcers and pitting scars in patients with pathologic FOI. Exemplary depiction of the location of current digital ulcer and/
or pitting scars (DU/PS) projected onto a fluorescence optical imaging frame 62 seconds after application of indocyanine green (ICG). The initial
enhancement (IE) has already taken place in all fingers with the first strong signal proximal to region 0 in digit II of the right hand
Table 3 Skin score of SSc patients depending on the results of fluorescence optical imaging
Mean skin score [±SD] Initial enhancement Maximum distal distribution
Pathologica Normal p value Pathologica Normal p value
Total (range 0–51) 10.2 [±8.2] 6.4 [±7.6] p = 0.0234 17.3 [±8.9] 7.2 [±6.8] p = 0.0003
Hands (range 0–12) 5.4 [±2.9] 3.2 [±2.7] p = 0.0037 8.24 [±2.3] 3.9 [±2.6] p < 0.0001
Left hand (range 0–6) 2.8 [±1.5] 1.6 [±1.3] p = 0.0013 3.9 [±1.1] 2.0 [±1.4] p = 0.0018
Right hand (range 0–6) 2.8 [±1.6] 1.8 [±1.4] p = 0.0163 4.3 [±1.2] 2.0 [±1.4] p = 0.0002
aAt least one finger with pathologic findings in the respective patient (first two rows) or hand (last two rows)
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patients with and without these complications. No signifi-
cant associations of FOI results and smoking habits,
disease duration or BMI were found (data not shown).
While a strong screening method due to its high sensi-
tivity, one of capillaroscopy’s drawbacks is the low speci-
ficity regarding capillaroscopy patterns. A combination
of capillaroscopy and FOI showed an important specifi-
city increase when comparing patients with and without
current DU/PS. Therefore, FOI can be considered as a
new, relatively fast and promising tool that could be
helpful in the assessment and the exact localization of
malperfused areas in patients with systemic sclerosis. So
far, FOI has mainly been used in the diagnosis of arth-
ritis such as rheumatoid arthritis and psoriatic arthritis.
They focused on areas of increased signal intensity by
analysing ICG distribution in order to identify joint in-
flammation [1–3]. Pfeil et al. made first attempts to
examine patients with SSc by FOI to visualise inflamed
tissue [7]. This greatly differs from the novel approach
taken in the present work as it represents an effort to
examine and quantify tissue nutrition and malperfusion
instead of inflammation. We focused on the analysis of
(low) ICG enhancement to measure the arterial distribu-
tion of the colouring agent, which revealed areas with
insufficient FOI staining in SSc patients. Associations
between FOI enhancement patterns and present signs of
ischemia such as digital ulcers and pitting scars support
our approach.
There have been a few other emerging imaging
methods trying to investigate peripheral blood perfusion
in SSc patients [30]: different techniques have shown
promising results in recent years, among them laser
speckle contrast analysis (LASCA) [14, 31], laser Dop-
pler imaging (LDI), laser speckle contrast imaging
(LSCI) and laser Doppler flowmetry (LDF); all of them
non-invasive. [30] LASCA, LDI and LDF proved to
discriminate SSc patients from those with primary
Raynaud’s phenomenon and/or healthy subjects. [32–34]
Low blood flow detected by LASCA and LDF was asso-
ciated with the late pattern in NC [33, 35] and improved
under vasoactive therapies [14, 33]. There have also been
first results showing that colour Doppler ultrasonog-
raphy of the arteries of the fingers and hands is linked to
the presence of digital ulcers/pitting scars [36]. Other
new techniques that are being investigated momentarily
are thermography and optical Doppler tomography and
spectroscopy [30].
Similar to LASCA and LDF, we showed that FOI was
able to discriminate between SSc patients and healthy
controls and that its findings were associated with a late
pattern capillaroscopy. Pfeil et al. [7] also demonstrated
a change in FOI pattern under vasoactive treatment,
which should be investigated for this study’s protocol in
the future. One of FOI’s limitations might be the
intravenous application of ICG, especially in compari-
son to those non-invasive methods to measure blood
perfusion and capillaroscopy. While not reaching sensi-
tivity and specificity levels of the CSURI (capillaro-
scopic skin ulcer risk index), analysis of FOI findings
are not limited to the presence of megacapillaries and
therefore applicable to almost all SSc patients (i.e. pa-
tients with early pattern capillaroscopy) [16, 17, 25].
Another aspect, which needs to be considered when
interpreting FOI results, is the proportional character
of the results. As the total ICG signal varies depending
on factors like the current cardiovascular state of the
subject, the speed of the injection, or the effective con-
centration of ICG in the blood, the signal is depicted as
a proportion of the strongest signal in the examined
area. As a consequence, FOI depicts microvascular dis-
turbances in the hand, not the absolute blood volume
reaching the hand.
FOI was conducted in a mean time of 15 minutes –
including preparation and analysis. Also, the examin-
ation itself can be run by a trained medical assistant and
does not require the presence of a medical physician
until the point of analysis. This time-saving side of FOI
could prove a valuable asset in clinical daily practice
where most patients already present with intravenous
catheters. Furthermore, our study revealed a consider-
able level of reliability for this new method.
While the comparison of SSc patients and healthy
subjects in this report is of cross-sectional design, SSc
patients will be further investigated as part of a longitu-
dinal study with the objective to identify the predictive
value of FOI and other diagnostic methods regarding the
development of future digital ulcers.
Study limitations include the relatively low number of
participants as well as the age differences between the
healthy cohort and the SSc group. Due to the centre’s
speciality, patients with severe systemic sclerosis were
more frequent in our cohort than in the SSc population
(i.e. higher incidence of DU/PS). We also observed diffi-
culties in the analysis of FOI staining in patients with se-
vere sclerodactyly. Even though our primary objective
was the assessment of microcirculation, we observed an
overlap of seemingly inflamed joints (as seen in Prima-
VistaMode, the composite image of the examination)
and the region of initial ICG enhancement in small share
of patients (data not shown). Here, an interference of in-
flammation and initial enhancement cannot completely
be ruled out. Additionally, Pfeil et al. [7] described areas
of ICG enhancement, which were interpreted as soft
tissue inflammation. While we focused on areas of di-
minished perfusion, the potential interactions of joint
as well as soft tissue inflammation and circulation
disturbances should be investigated in more detail in
future studies.
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While we examined three patients with primary
Raynaud’s (unpublished data) who mostly showed en-
hancement patterns similar to the healthy cohort, a
more extensive investigation into FOI in primary
Raynaud’s patients as well as a comparison to patients
with secondary Raynaud’s is needed.
Conclusions
Further investigations into FOI’s ability to detect abnor-
mal microcirculation are suggested to prove FOI valid-
ation data in SSc patients. A software for automatically
generated disease activity values (DACT) has been devel-
oped for patients with inflamed joints, but not yet for
areas of malperfusion in the hands.
The present work and subsequent results represent
first attempts at a broader detection of vasculopathy in
SSc using the FOI method. FOI could be a novel tool for
the assessment of symptomatic vasculopathy and could
provide additional assistance in the risk stratification of
digital ulcers.
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